Treatments targeting the liver could treat type 2 diabetes

Home / Pharmaceutical Updates / Treatments targeting the liver could treat type 2 diabetes

Treatments targeting the liver could treat type 2 diabetes

doctor examining scans on computer

New research suggests a new treatment pathway for type 2 diabetes. choja/Getty Images

  • Researchers have investigated the link between fatty liver disease and key markers of type 2 diabetes in mice.
  • The results suggest that reducing the production of the neurotransmitter GABA in the liver could normalize blood glucose levels, decrease appetite, and lead to weight loss.
  • The researchers say that the treatment pathway may exclusively work among people with obesity.

Type 2 diabetes is characterized by high blood sugar levels caused by insulin resistance.

Insulin is a hormone that helps glucose enter cells, where it can be used for energy or stored for future use. Insulin resistance happens when cells in the body do not respond well to insulin and thus do not remove glucose from the blood.

In type 2 diabetes, insulin resistance also increases the body’s production of insulin, which can lead to increased appetite, high blood pressure, and weight gain.

Previous research has shown that type 2 diabetes is strongly linked to overweight and fatty liver disease, which involves storing excess fat in the liver. According to the Centers for Disease Control and Prevention (CDC), 89% of people with diabetes has overweight.

While scientists have long suspected that excess fat in the liver might cause type 2 diabetes, exactly how this could be has remained a mystery.

Recently, researchers from the University of Arizona, Washington University in St. Louis, the University of Pennsylvania, and Northwestern University conducted two studies to piece apart the underlying mechanisms linking fatty liver disease with glucose homeostasis, which is the balance between insulin and glucose in the blood.

They found that insulin sensitivity can be restored within days of reducing excess production of the neurotransmitter GABA in the liver and that long-term treatment may lead to decreased appetite and weight loss.

Neurotransmitters are sent between nerves to allow the brain and different parts of the body to communicate. GABA is an inhibitory neurotransmitter, meaning that it decreases signaling in the nervous system.

“When the liver produces GABA, it decreases [the] activity of those nerves that run from the liver to the brain. Thus, fatty liver, by producing GABA, is decreasing firing activity to the brain,” explained study author Dr. Benjamin Renquist. “That decrease in firing is sensed by the central nervous system, which changes outgoing signals that affect glucose homeostasis.”

The researchers have published their findings in Cell Reports.

Leave a Reply

Your email address will not be published.